AbbVie has filed a legal challenge seeking to narrow and clarify who counts as an "eligible patient" under the federal 340B ...
This story was originally published by CalMatters. Sign up for their newsletters. Guest Commentary written by Julie Gill Shuffield Julie Gill Shuffield is executive director of Patients Come ...
On April 8, Cantor Fitzgerald lowered its price recommendation on AbbVie Inc. (NYSE:ABBV) to $240 from $250. It kept an ...
Pharmacy benefit managers (PBMs) are now facing the same transparency and accountability requirements that employers and ...
The enterprise-grade workflow automation solution expands Plenful’s Regulatory Compliance and Revenue Optimization suite with ...
Pharmalittle: We’re reading about top pharma lobbyist stepping down, genes and GLP-1 drugs, and more
Steve Ubl, chief executive of PhRMA, plans to step down at the end of the year, after more than a decade leading the main ...
Investigative journalist Nick Shirley created a nationwide sensation when he uncovered $110 million in suspicious government ...
AbbVie has filed a lawsuit against the U.S. government, seeking clearer guidance on patients eligible for a drug discount ...
Tuesday’s bill gives powers to the Attorney General’s Office to further enforce state law that prohibits manufacturers from ...
Pharmaceutical companies are spending hundreds of millions lobbying elected officials to try and persuade them to gut the ...
Drug companies want to end it. This is not a partisan issue. It is a math issue. And for the patients and communities we serve, it is a survival issue.
The 340B Drug Pricing Program was created with a narrow and defensible purpose: to allow safety-net healthcare providers to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results